Myasthenia gravis is caused by antibodies to the acetylcholine receptor, muscle-specific
kinase, low-density lipoprotein receptor-related protein 4, or possibly yet unidentified …

Introduction: Exon skipping is a therapeutic approach for Duchenne muscular dystrophy
(DMD) that has been in development for close to two decades. This approach uses …

Mitochondrial Ca2+ uptake has key roles in cell life and death. Physiological Ca2+ signaling
regulates aerobic metabolism, whereas pathological Ca2+ overload triggers cell death …

Myasthenia gravis (MG) is a severely debilitating autoimmune disease that is due to a
decrease in the efficiency of synaptic transmission at neuromuscular synapses. MG is …

In generalized myasthenia gravis (MG) patients without detectable acetylcholine receptor
(AChR) antibodies (SNMG), the thymus is often reported as “normally involuted.” We …

Myasthenia gravis is a paralytic disorder with autoantibodies against acetylcholine receptors
at the neuromuscular junction. A proportion of patients instead has antibodies against …

Objective: The objective of this study is to comprehensively define the genetic basis of early
onset myasthenia gravis (EOMG). Methods: We have carried out a 2‐stage genome‐wide …

Duchenne muscular dystrophy (DMD) is a muscular dystrophy with high incidence of
learning and behavioural problems and is associated with neurodevelopmental disorders …

Objective Duchenne muscular dystrophy (DMD) is characterized by progressive muscle
weakness caused by DMD gene mutations leading to absence of the full‐length dystrophin …

With the rapid increase in the number of interventional clinical trials in Duchenne muscular
dystrophy (DMD) over the past few years, the need for a frank and honest discussion …